Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients

J. A. Vazquez; S. Gupta; A. Villanueva

doi:10.1007/s100960050185

Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients

J. A. Vazquez, S. Gupta, A. Villanueva

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

The aim of the study was to investigate the use of granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjunctive treatment for clinically refractory mucosal candidiasis in patients with advanced AIDS. Three patients with advanced AIDS and oropharyngeal candidiasis clinically refractory to azoles or amphotericin B received GM-CSF for 14 days along with either fluconazole or amphotericin B. All three patients showed clinical improvement and mycological improvement without any adverse events. Thus, GM-CSF may be a possible alternative as adjunctive therapy in the management of refractory mucosal candidiasis in patients with advanced AIDS.

Original language	English (US)
Pages (from-to)	781-783
Number of pages	3
Journal	European Journal of Clinical Microbiology and Infectious Diseases
Volume	17
Issue number	11
DOIs	https://doi.org/10.1007/s100960050185
State	Published - 1998
Externally published	Yes

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s100960050185

Cite this

@article{8c942477728640f39e82f1e2ba2213a6,

title = "Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients",

abstract = "The aim of the study was to investigate the use of granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjunctive treatment for clinically refractory mucosal candidiasis in patients with advanced AIDS. Three patients with advanced AIDS and oropharyngeal candidiasis clinically refractory to azoles or amphotericin B received GM-CSF for 14 days along with either fluconazole or amphotericin B. All three patients showed clinical improvement and mycological improvement without any adverse events. Thus, GM-CSF may be a possible alternative as adjunctive therapy in the management of refractory mucosal candidiasis in patients with advanced AIDS.",

author = "Vazquez, {J. A.} and S. Gupta and A. Villanueva",

year = "1998",

doi = "10.1007/s100960050185",

language = "English (US)",

volume = "17",

pages = "781--783",

journal = "European Journal of Clinical Microbiology and Infectious Diseases",

issn = "0934-9723",

publisher = "Vieweg",

number = "11",

}

TY - JOUR

T1 - Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients

AU - Vazquez, J. A.

AU - Gupta, S.

AU - Villanueva, A.

PY - 1998

Y1 - 1998

N2 - The aim of the study was to investigate the use of granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjunctive treatment for clinically refractory mucosal candidiasis in patients with advanced AIDS. Three patients with advanced AIDS and oropharyngeal candidiasis clinically refractory to azoles or amphotericin B received GM-CSF for 14 days along with either fluconazole or amphotericin B. All three patients showed clinical improvement and mycological improvement without any adverse events. Thus, GM-CSF may be a possible alternative as adjunctive therapy in the management of refractory mucosal candidiasis in patients with advanced AIDS.

AB - The aim of the study was to investigate the use of granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjunctive treatment for clinically refractory mucosal candidiasis in patients with advanced AIDS. Three patients with advanced AIDS and oropharyngeal candidiasis clinically refractory to azoles or amphotericin B received GM-CSF for 14 days along with either fluconazole or amphotericin B. All three patients showed clinical improvement and mycological improvement without any adverse events. Thus, GM-CSF may be a possible alternative as adjunctive therapy in the management of refractory mucosal candidiasis in patients with advanced AIDS.

UR - http://www.scopus.com/inward/record.url?scp=0032440451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032440451&partnerID=8YFLogxK

U2 - 10.1007/s100960050185

DO - 10.1007/s100960050185

M3 - Article

C2 - 9923519

AN - SCOPUS:0032440451

SN - 0934-9723

VL - 17

SP - 781

EP - 783

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

IS - 11

ER -

Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this